United Therapeutics (UTHR) Tops Q4 EPS Views; Guides FY13 Revs
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $542.66 -0.13%
EPS Growth %: +11.9%
Financial Fact:
Diluted (in shares): 46.2M
Today's EPS Names:
CGEH, NAKA, APOG, More
EPS Growth %: +11.9%
Financial Fact:
Diluted (in shares): 46.2M
Today's EPS Names:
CGEH, NAKA, APOG, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q4 EPS of $1.65, $0.40 better than the analyst estimate of $1.25. Revenue for the quarter came in at $243.82 million versus the consensus estimate of $233.41 million.
United Therapeutics sees FY2013 revenue of $952.4 million to $1.05 billion, versus the consensus of $990.59 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
United Therapeutics sees FY2013 revenue of $952.4 million to $1.05 billion, versus the consensus of $990.59 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
- JPMorgan Starts TIME dotCom Berhad (TDC:MK) at Overweight
- Investing.com’s stocks of the week
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
